Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Authors

Robert T Naismith, Washington University School of Medicine in St. Louis
et al

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)

Publication Date

11-1-2020

Volume

26

Issue

13

First Page

1729

Last Page

1739

Document Type

Open Access Publication

DOI

10.1177/1352458519881761

Rights and Permissions

Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler. 2020 Nov;26(13):1729-1739. doi: 10.1177/1352458519881761. © The Author(s), 2019. CC-BY-NC

Recommended Citation

Naismith, Robert T and et al, "Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study." Multiple sclerosis (Houndmills, Basingstoke, England). 26, 13. 1729 - 1739. (2020).
https://digitalcommons.wustl.edu/oa_4/185